Skip to content
Screener
Supernus Pharmaceuticals logo

Supernus Pharmaceuticals

SUPN

Indivior is a global pharmaceutical company specializing in the development and commercialization of medicines for substance use disorders and other serious mental illnesses.

Market cap
$1.61B-37.1%
Revenue$1.4B+16.3%
Net income$450.0M+252%
Free cash flow$31.0M—
EPS (diluted)$3.58+254%
Trailing twelve months · change vs. prior year

Earnings

Next report

Date not yet announced

Financials

Q3 2026

Income statement

See full
Revenue$356.0M+13.4%
Gross profit$305.0M+32.6%
Operating income$180.0M+319%
Net income$137.0M+226%
EPS (diluted)$1.12+239%

Balance sheet

See full
Cash & equivalents$305.0M-31.5%
Total debt$501.0M+40.7%
Total equity-$60.0M+71.0%
Total assets$1.3B-5.9%

Cash flow

See full
Operating cash flow$97.0M—
CapEx$14.0M-30.0%
Free cash flow$83.0M—

Valuation & ratios

Valuation

See full
Market cap$1.61B-37.1%
Enterprise value$1.8B-28.2%
P/E3.6×-16.7×
P/S1.2×-1.0×

Profitability

See full
Gross margin85%+4.5pp
Operating margin40.6%+21.4pp
Net margin32.8%+21.9pp
FCF margin15.8%—

Returns & leverage

See full
Current ratio0.6×-0.3×

Segments

By product

See full
SUBLOCADE$267.0M+21.9%
Sublingual & other$53.0M+3.9%
PERSERIS$2.0M-66.7%

By segment

See full
Reportable Segment$356.0M+13.4%

By geography

See full
Rest of World$48.0M+2.1%

Competitors

Profile

Indivior is a global pharmaceutical company specializing in the development and commercialization of medicines for substance use disorders and other serious mental illnesses. The company focuses on addressing the opioid crisis through innovative long-acting injectable and transmucosal drug delivery technologies. Its value proposition is centered on providing treatment solutions that mitigate the risks of misuse and diversion while improving patient adherence.

Competitive position

A leading provider of buprenorphine-based treatments for opioid use disorder with a strong patent portfolio and specialized regulatory expertise in controlled substances.

GeographiesUnited States, Canada, Australia, European Union
Customer segmentsPatients with substance use disorders, Public and private insurers, Government health agencies
Business modelResearch and Development, Manufacturing, Intellectual Property Licensing
SuppliersActive pharmaceutical ingredient (API) suppliers, Contract manufacturing organizations, Specialized chemical suppliers
CustomersWholesale distributors, Retail pharmacies, Government health systems (Medicaid/Medicare), Correctional facilities
Listed2012
Employees778.0
CEOJack A. Khattar
FilingsSEC EDGAR

FAQ

What is Supernus Pharmaceuticals's market cap?
Supernus Pharmaceuticals (SUPN) has a market capitalization of $1.6B and trades on NASDAQ.
What is Supernus Pharmaceuticals's revenue and profitability?
Supernus Pharmaceuticals generated $1.4B in trailing twelve-month revenue with net income of $450.0M, representing a net margin of 32.8%. Gross margin stands at 85.0%, with free cash flow of $31.0M. The latest reported period is Q3 2026.
Who are Supernus Pharmaceuticals's competitors?
Supernus Pharmaceuticals's key competitors include Alkermes, Rapport Therapeutics, Inc. Common Stock, Serina Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
What subsidiaries does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals's subsidiaries include Indivior U.K. Limited.
Where is Supernus Pharmaceuticals headquartered?
Supernus Pharmaceuticals is headquartered in United States of America and employs approximately 778 people. It has been publicly traded since 2012.